(Institución)/></a>
				</td>
				<td class= (Institución)
   (Nuevo usuario)
Ayuda  | Contacto  |  Castellano English  
 

Dadun > Depósito Académico > Clínica Universidad de Navarra > Farmacología clínica > DA - CUN - Farmacología clínica - Artículos de revista >

TAK1 mRNA Expression in the Tumor Tissue of Locally Advanced Head and Neck Cancer Patients
Autor(es) : Honorato, B. (Beatriz)
Alcalde, J. (Juan)
Martinez-Monge, R. (Rafael)
Garcia-Foncillas, J. (Jesús)
Zabalegui, N. (Natalia)
Palabras clave : Real-time PCR
Molecular markers
TAK1
Fecha incorporación: 2008
Editorial : Libertas Academica
Versión del editor: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2733096/?tool=pubmed
ISSN: 1177-6250
Cita: Honorato B, Alcalde J, Martinez-Monge R, Zabalegui N, Garcia-Foncillas J. TAK1 mRNA expression in the tumor tissue of locally advanced head and neck cancer patients. Gene Regul Syst Bio 2008 Feb 14;2:63-70.
Resumen
Resistance to radio and chemotherapy is one of the major drawbacks in the progression of head and neck squamous cell cancer (HNSCC) patients, evidencing the importance of finding optimum molecular prognosis markers to develop personalized treatment schedules. TGF-β effector TAK1 activity has been related to a greater aggressiveness in several types of cancer (Kondo et al. 1998; Edlund et al. 2003; Kaur et al. 2005) and, although there has been described no significant implication of TAK1 in HNSCC development, we have further examined the role of its mRNA expression as a marker of prognosis in HNSCC. Fifty-nine advanced HNSCC patients were recruited for the study. The tumor expression of TAK1 mRNA was analyzed with RT-PCR using Taqman technology and its relationship with the clinical outcome of the patients studied. TAK1 mRNA expression was lower in patients that relapsed than in those that did not, but the difference was only significant between the patients that showed response to treatment (p < 0.001). ROC curve analyses pointed a 0.5 expression ratio TAK1/B2M value as an optimum cut-off point for relapse and response. Our data suggest the TAK1 mRNA analysis by Taqman RT-PCR can predict the risk of relapse in HNSCC patients.
Enlace permanente: http://hdl.handle.net/10171/23495
Aparece en las colecciones: DA - CUN - Oncología radioterápica - Artículos de revista
DA - CUN - Otorrinolaringología - Artículos de revista
DA - CIMA - Oncología - Inmunoterapia - Artículos de Revista
DA - CUN - Oncología médica - Artículos de revista
DA - CUN - Unidad de Genética clínica - Artículos de revista
DA - CUN - Farmacología clínica - Artículos de revista

Ficheros en este registro:
Fichero:  Gene Regul Syst Bio 2008. 63.pdf
Descripción: 
Tamaño:  454,66 kB
Formato:  Adobe PDF
 Visualizar / Abrir 

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.